Drugs / CERLAPIRDINE
CERLAPIRDINE
also known as
SAM-531 · Cerlapirdina · CERLAPIRDINE HYDROCHLORIDE · PF-05212365 · SAM-531 FREE BASE · Sam-531 hydrochloride · WAY-262,531
Small molecule targets HTR6 via inhibition
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01253655 | Nov 2010 → Mar 2011 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00966966 | Sep → Dec 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00906191 | May → Aug 2009 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00745576 | Oct → Dec 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00519298 | Oct 2007 → Mar 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00480818 | Sep 2006 → Jul 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00479297 | May 2006 → Feb 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00479700 | May → Jul 2006 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT00895895 | May 2009 → May 2011 | Alzheimer disease | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT00481520 | Jun 2007 → Jan 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00726115 Comparator | Aug 2008 → Feb 2009 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00479349 Comparator | May 2007 → Jan 2008 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CERLAPIRDINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103880 ↗ |
| Known as | Cerlapirdina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103880 ↗ |
| Known as | CERLAPIRDINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103880 ↗ |
| Known as | PF-05212365 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01253655 ↗ |
| Known as | SAM-531 | “A Phase 1, Open-Label Study To Evaluate 5-HT6 Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]PF-04171252 Following Single Oral Dose...” NCT01253655 ↗11“2 single doses of 5 mg SAM-531 (capsules)” NCT00966966 ↗ |
| Known as | SAM-531 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103880 ↗ |
| Known as | Sam-531 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103880 ↗ |
| Known as | WAY-262,531 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2103880 ↗ |
| Action | Inhibit | “Serotonin 6 (5-HT6) receptor antagonist” CHEMBL2103880 ↗ |
| Modality | Small molecule | — CHEMBL2103880 ↗ |
| Route | Oral | “SAM-531 Administered Orally” NCT00479297 ↗ |
| Target | HTR6 | “Serotonin 6 (5-HT6) receptor antagonist” CHEMBL2103880 ↗ |